{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tofacitinib+2+mg", "query": { "intervention": "Tofacitinib 2 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 55, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tofacitinib+2+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-21T03:29:01.736Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06654882", "title": "Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Polyarticular Course Juvenile Idiopathic Arthritis (JIA)" ], "interventions": [ { "name": "TNFi (Tumor Necrosis Factor inhibitor) medication", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 400, "start_date": "2026-01-09", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-09-21T03:29:01.736Z", "location_count": 4, "location_summary": "San Francisco, California • Gainesville, Florida • Hackensack, New Jersey + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06654882" }, { "nct_id": "NCT01710046", "title": "Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "(CP-6890,550) Tofacitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "(CP-690,550) Tofacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2013-03", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2015-04-13", "last_synced_at": "2026-09-21T03:29:01.736Z", "location_count": 5, "location_summary": "Los Angeles, California • Tampa, Florida • Dallas, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01710046" }, { "nct_id": "NCT00483756", "title": "Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Cyclosporine", "type": "DRUG" }, { "name": "CP-690,550", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 338, "start_date": "2007-08", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2013-03-14", "last_synced_at": "2026-09-21T03:29:01.736Z", "location_count": 37, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00483756" }, { "nct_id": "NCT05662228", "title": "Therapies for Down Syndrome Regression Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Down Syndrome", "Regression" ], "interventions": [ { "name": "Lorazepam", "type": "DRUG" }, { "name": "Intravenous immunoglobulin (IVIG)", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "8 Years to 30 Years" }, "enrollment_count": 66, "start_date": "2023-06-29", "completion_date": "2026-05-28", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-21T03:29:01.736Z", "location_count": 2, "location_summary": "Los Angeles, California • Aurora, Colorado", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05662228" }, { "nct_id": "NCT01204112", "title": "Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Tasocitinib (CP-690,550) plus Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 12, "start_date": "2010-09", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2010-10-22", "last_synced_at": "2026-09-21T03:29:01.736Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01204112" }, { "nct_id": "NCT00960440", "title": "Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "CP-690,550", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 399, "start_date": "2009-10", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2018-12-19", "last_synced_at": "2026-09-21T03:29:01.736Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Farmington", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00960440" }, { "nct_id": "NCT01831466", "title": "Tofacitinib Ointment For Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis Vulgaris", "Psoriasis" ], "interventions": [ { "name": "tofacitinib ointment 20 mg/g", "type": "DRUG" }, { "name": "tofacitinib ointment 10 mg/g", "type": "DRUG" }, { "name": "placebo ointment (vehicle)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 476, "start_date": "2013-05", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2015-11-25", "last_synced_at": "2026-09-21T03:29:01.736Z", "location_count": 29, "location_summary": "Hot Springs, Arkansas • Bakersfield, California • Irvine, California + 22 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01831466" }, { "nct_id": "NCT03681275", "title": "Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diaphragm Injury" ], "interventions": [ { "name": "Tofacitinib 10 MG [Xeljanz]", "type": "DRUG" }, { "name": "Placebo to match Tofacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2019-09-03", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2024-11-25", "last_synced_at": "2026-09-21T03:29:01.736Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03681275" }, { "nct_id": "NCT03414502", "title": "Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Minocycline", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 400, "start_date": "2007-12-10", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-21T03:29:01.736Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03414502" }, { "nct_id": "NCT04111614", "title": "A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Tofacitinib tablet", "type": "DRUG" }, { "name": "Tofacitinib Oral Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 12, "start_date": "2019-10-11", "completion_date": "2019-12-12", "has_results": false, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-09-21T03:29:01.736Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04111614" } ] }